Normal human serum inhibits Acanthamoeba (encephalitis isolate) binding to and cytotoxicity of human brain microvascular endothelial cells, which constitute the blood-brain barrier. Zymographic assays revealed that serum inhibits extracellular protease activities of acanthamoebae. But it is most likely that inhibition of specific properties of acanthamoebae is a consequence of the initial amoebicidal-amoebistatic effects induced by serum. For example, serum exhibited amoebicidal effects; i.e., up to 50% of the exposed trophozoites were killed. The residual subpopulation, although viable, remained static over longer incubations. Interestingly, serum enhanced the phagocytic ability of acanthamoebae, as measured by bacterial uptake. Overall, our results demonstrate that human serum has inhibitory effects on Acanthamoeba growth and viability, protease secretions, and binding to and subsequent cytotoxicity for brain microvascular endothelial cells. Conversely, Acanthamoeba phagocytosis was stimulated by serum.Acanthamoebae are free-living amoebae that can cause fatal Acanthamoeba granulomatous encephalitis (AGE), which is predominantly associated with immunocompromised patients such as human immunodeficiency virus (HIV)-AIDS patients (reviewed in references 9, 11, and 15). In addition, patients suffering from other diseases such as diabetes, malignancies, malnutrition, or alcoholism or who have debilitated immune systems because of immunosuppressive therapy or other complications are also susceptible to AGE infections. With the growing HIV pandemic, it is reasonable to predict an increase in the number of opportunistic infections. This is particularly worrying in developing countries, where HIV patients have limited or no access to novel antiretroviral therapies. Thus, there is a need for continued efforts to (i) increase awareness, (ii) develop rapid diagnostic methods, and (iii) understand basic molecular mechanisms of host-parasite interactions, which should help develop preventative and/or therapeutic strategies. One of the major steps in AGE is invasion of the bloodstream by amoebae, followed by their hematogenous spread (12). Acanthamoeba entry into the central nervous system most likely occurs at blood-brain barrier sites (12; personal communication with the late A. J. Martinez, University of Pittsburgh School of Medicine). Recent studies have shown that acanthamoebae exhibit multifactorial properties to produce damage of human brain microvascular endothelial cells (HBMEC), which constitute the blood-brain barrier (1-3, 16). However, the effects of serum on Acanthamoeba interactions with HBMEC are not known and were the objectives of the present study.Acanthamoeba castellanii (ATCC 50494) belonging to the T1 genotype was originally isolated from an AGE patient and routinely grown in PYG medium (0.75% Proteose Peptone, 0.75% yeast extract, 1.5% glucose) at 30°C, and the medium was refreshed 17 to 20 h prior to experiments as previously described (16). This resulted in more than 95% acanthamoebae in the trophozo...